Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1973 1
1975 1
1976 1
1977 1
1980 1
1981 5
1982 1
1983 2
1984 4
1985 6
1986 4
1987 2
1988 2
1989 5
1990 5
1991 4
1992 7
1993 7
1994 11
1995 7
1996 9
1997 11
1998 10
1999 9
2000 15
2001 13
2002 12
2003 17
2004 10
2005 22
2006 20
2007 21
2008 18
2009 18
2010 20
2011 18
2012 28
2013 26
2014 32
2015 33
2016 31
2017 31
2018 37
2019 49
2020 71
2021 68
2022 65
2023 63
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

757 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hypotrichosis 6"
Page 1
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Piraccini BM, et al. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. Epub 2021 Oct 25. J Eur Acad Dermatol Venereol. 2022. PMID: 34634163 Free PMC article. Clinical Trial.

Change from baseline in target area hair count (TAHC) at week 24 (primary efficacy endpoint) was significantly greater with topical finasteride than placebo (adjusted mean change 20.2 vs. 6.7 hairs; P < 0.001), and numerically similar between topical and oral finasterid

…
Change from baseline in target area hair count (TAHC) at week 24 (primary efficacy endpoint) was significantly greater with topical finaster …
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. King B, et al. Lancet. 2023 May 6;401(10387):1518-1529. doi: 10.1016/S0140-6736(23)00222-2. Epub 2023 Apr 14. Lancet. 2023. PMID: 37062298 Clinical Trial.
The sponsor, patients, and investigators were masked to treatment, and all patients received the same number of tablets to maintain masking. The primary endpoint was Severity of Alopecia Tool (SALT) score 20 or less at week 24. The primary endpoint was assessed in all assi …
The sponsor, patients, and investigators were masked to treatment, and all patients received the same number of tablets to maintain masking. …
Current application of mesotherapy in pattern hair loss: A systematic review.
Tang Z, Hu Y, Wang J, Fan Z, Qu Q, Miao Y. Tang Z, et al. J Cosmet Dermatol. 2022 Oct;21(10):4184-4193. doi: 10.1111/jocd.14900. Epub 2022 Mar 14. J Cosmet Dermatol. 2022. PMID: 35253335 Review.
RESULTS: We got 336 studies from searched databases, and 12 studies were included after selection process. A total of 253 males and 274 females participated in 6 randomized control trials, 2 nonrandomized controlled trials, and 3 observational studies. ...
RESULTS: We got 336 studies from searched databases, and 12 studies were included after selection process. A total of 253 males and 274 fema …
Systematic review of mesotherapy: a novel avenue for the treatment of hair loss.
Gupta AK, Polla Ravi S, Wang T, Talukder M, Starace M, Piraccini BM. Gupta AK, et al. J Dermatolog Treat. 2023 Dec;34(1):2245084. doi: 10.1080/09546634.2023.2245084. J Dermatolog Treat. 2023. PMID: 37558233 Free article. Review.
This systematic review aims to summarize the current literature that evaluates the efficacy of this technique for the treatment of hair loss and provides an overview of the results observed. Of the 416 records identified, 27 articles met the inclusion criteria. To date, me …
This systematic review aims to summarize the current literature that evaluates the efficacy of this technique for the treatment of hair loss …
5% Minoxidil: treatment for female pattern hair loss.
Gupta AK, Foley KA. Gupta AK, et al. Skin Therapy Lett. 2014 Nov-Dec;19(6):5-7. Skin Therapy Lett. 2014. PMID: 25807073 Free article. Review.
Recent Phase III clinical trials demonstrated the efficacy of once daily 5% minoxidil foam for treatment of FPHL, where a significant change from baseline in the target area hair count was observed compared to placebo. Similar changes in hair count for 5% foam and twice da …
Recent Phase III clinical trials demonstrated the efficacy of once daily 5% minoxidil foam for treatment of FPHL, where a significant change …
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
Guttman-Yassky E, Renert-Yuval Y, Bares J, Chima M, Hawkes JE, Gilleaudeau P, Sullivan-Whalen M, Singer GK, Garcet S, Pavel AB, Lebwohl MG, Krueger JG. Guttman-Yassky E, et al. Allergy. 2022 Mar;77(3):897-906. doi: 10.1111/all.15071. Epub 2021 Sep 6. Allergy. 2022. PMID: 34460948 Free PMC article. Clinical Trial.
The primary outcome was change from baseline in the Severity of Alopecia Tool (SALT) score at week 24; secondary outcomes included a range of measures of hair regrowth. ...At week 24, disease worsening was documented in the placebo arm, with a least-squares mean change in …
The primary outcome was change from baseline in the Severity of Alopecia Tool (SALT) score at week 24; secondary outcomes included a …
Microneedling in androgenetic alopecia; comparing two different depths of microneedles.
Faghihi G, Nabavinejad S, Mokhtari F, Fatemi Naeini F, Iraji F. Faghihi G, et al. J Cosmet Dermatol. 2021 Apr;20(4):1241-1247. doi: 10.1111/jocd.13714. Epub 2020 Sep 29. J Cosmet Dermatol. 2021. PMID: 32897622

RESULTS: Compared with the baseline, a significant increase in hair count and hair thickness was observed in all three groups after completion of the treatment course (P < .05). ...Investigator's evaluation of hair regrowth was significantly greater in group A (P = .04)

…
RESULTS: Compared with the baseline, a significant increase in hair count and hair thickness was observed in all three groups after c …
Randomized trial of aromatherapy. Successful treatment for alopecia areata.
Hay IC, Jamieson M, Ormerod AD. Hay IC, et al. Arch Dermatol. 1998 Nov;134(11):1349-52. doi: 10.1001/archderm.134.11.1349. Arch Dermatol. 1998. PMID: 9828867 Clinical Trial.
Similarly, the degree of improvement was measured by 2 methods: a 6-point scale and computerized analysis of traced areas of alopecia. RESULTS: Nineteen (44%) of 43 patients in the active group showed improvement compared with 6 (15%) of 41 patients in the control g …
Similarly, the degree of improvement was measured by 2 methods: a 6-point scale and computerized analysis of traced areas of alopecia …
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS. King B, et al. J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20. J Am Acad Dermatol. 2021. PMID: 33757798 Free article. Clinical Trial.
The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary efficacy endpoint was the proportion of patients achieving 30% improvement in SALT score (SALT(30)). ...At week 24, least-squares mean d …
The primary efficacy endpoint was a 24-week change from baseline in the Severity of Alopecia Tool (SALT) score. The key secondary eff …
Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Hordinsky M, et al. Pediatr Dermatol. 2023 Nov-Dec;40(6):1003-1009. doi: 10.1111/pde.15378. Epub 2023 Jul 17. Pediatr Dermatol. 2023. PMID: 37455588 Clinical Trial.
At Week 24, 17%-28% of adolescents achieved a Severity of Alopecia Tool (SALT) score 20 (20% scalp without hair) in the ritlecitinib 30 mg and higher treatment groups versus 0% for placebo. At Week 48, 25%-50% of patients had a SALT score 20 across ritlecitinib trea …
At Week 24, 17%-28% of adolescents achieved a Severity of Alopecia Tool (SALT) score 20 (20% scalp without hair) in the ritlecitinib …
757 results